Navigation Links
Health Enhancement Products Reacquires ProAlgaZyme(TM) Distribution and Marketing Rights
Date:10/2/2009

Company Better Positioned for Future Growth

SCOTTSDALE, AZ, Oct. 2 /PRNewswire-FirstCall/ - Health Enhancement Products, Inc. (OTC BB: HEPI.OB) and Changing Times Vitamins today announced, they have mutually agreed to terminate their current distribution agreement, in which Changing Times Vitamins had acquired the exclusive rights to distribute ProAlgaZyme (PAZ).

Under terms of the definitive agreement, HEPI retains all marketing and sales rights associated with the Company's proprietary ProAlgaZyme(TM) (PAZ) compound. HEPI will also retain control of all remaining inventory, labels, bottles, promotional materials, as well as customer contact information.

Peter Vitulli, Interim CEO of HEPI, commented, "Since joining the Company just a few short weeks ago, I have quickly recognized the immense potential that exists with our lead bioactive compound, PAZ. As such, I have initiated a series of steps to better position the Company for future growth. The first step is to control every aspect of PAZ's distribution, marketing and sales going forward. This decision is in the best interest of the Company as it allows us the freedom to evaluate multiple strategic options to maximize the true value of PAZ for our shareholders." Mr. Vitulli continued, "We continue to be greatly encouraged by the preliminary findings from Wayne State University and look forward to providing additional results in the coming weeks, along with more detailed information regarding the various opportunities available to the Company going forward."

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTC BB: HEPI) is a health & wellness company engaged in the development of dietary supplements, food additives and ingredients using only pure, all-natural compounds. The Company's premier product is ProAlgaZyme (PAZ), a liquid product drawn from living algae grown in purified water. The water in which the algae is grown is drawn off, filtered and bottled as ProAlgaZyme.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit http://www.heponline.com.

CONTACT: Health Enhancement Products, Inc., John Gorman, Director of Sales, (480) 385-3800, john@heponline.com; IR Contact: Howard Gostfrand, David Sasso, (305) 918-7000, info@amcapventures.com, www.amcapventures.com

SOURCE Health Enhancement Products, Inc.


'/>"/>
SOURCE Health Enhancement Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... They are musicians and librarians, fashion designers and ... fathers, from New England and around the nation. What do they have in common? ... in a beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff Hart Agencies, ... South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is announcing ... a brain tumor. , Jason Bauer and his family are longtime members of ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors ... the securement tape is painful for her. "This is why the co-inventor and I ... she said. , They then created a prototype of the patent-pending AV-AIR, a device ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... The study was published in the prestigious Journal of Veterinary Science & Medical ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John ... by donating a portion of proceeds to two local organizations: North Chicago Animal Control ... & Friends is a team of authorized and trained volunteers who support rescued ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016  Northwest Biotherapeutics (Nasdaq: ... "Company"), a biotechnology company developing DCVax® personalized immune ... the Nasdaq Staff has not accepted the Company,s ... Rules previously reported, and the Company has notified ... Company,s common stock from listing on Nasdaq.  Upon ...
(Date:12/7/2016)... --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... the ralinepag phase 2 trial.  Ralinepag is an oral, ... the treatment of pulmonary arterial hypertension (PAH). The study ... "This marks an important step in the development of ... our pipeline," said Amit Munshi , Arena,s President ...
(Date:12/7/2016)... Kan. , Dec. 7, 2016   Rx Savings ... West Virginia and its Public Employees Insurance Agency ... members access to their innovative healthcare software, ultimately saving money ... with PEIA and provide its members with access to our ... or a more effective, affordable therapy can be found," says ...
Breaking Medicine Technology: